Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. A role for systems biology approach in drug development. Part II - CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs

Michael A. Idowu

Research output: Contribution to journalArticle

1 Citation (Scopus)
10 Downloads (Pure)

Abstract

Cyclin-dependent kinases (CDKs) are key regulators of cell growth and proliferation. Impaired regulation of their activity leads to various diseases such as cancer and heart hypertrophy. Consequently, a number of CDKs are considered as targets for drug discovery. We review the development of inhibitors of CDK2 as anti-cancer drugs in the first part of the paper and in the second part, respectively, the development of inhibitors of CDK9 as potential therapeutics for heart hypertrophy. We argue that the above diseases are systems biology, or network diseases. In order to fully understand the complexity of the cell growth and proliferation disorders, in addition to experimental sciences, a systems biology approach, involving mathematical and computational modelling ought to be employed.
Original languageEnglish
Pages (from-to)2712-2715
Number of pages4
JournalBiotechnology and Biotechnological Equipment
Volume26
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Growth Disorders
Systems Biology
Cyclin-Dependent Kinases
Drug Delivery Systems
Cell Proliferation
Cardiomegaly
Growth
Pharmaceutical Preparations
Drug Discovery
Neoplasms
Therapeutics

Cite this

@article{cb924825142040a18d4e49d320ef3019,
title = "Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. A role for systems biology approach in drug development. Part II - CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs",
abstract = "Cyclin-dependent kinases (CDKs) are key regulators of cell growth and proliferation. Impaired regulation of their activity leads to various diseases such as cancer and heart hypertrophy. Consequently, a number of CDKs are considered as targets for drug discovery. We review the development of inhibitors of CDK2 as anti-cancer drugs in the first part of the paper and in the second part, respectively, the development of inhibitors of CDK9 as potential therapeutics for heart hypertrophy. We argue that the above diseases are systems biology, or network diseases. In order to fully understand the complexity of the cell growth and proliferation disorders, in addition to experimental sciences, a systems biology approach, involving mathematical and computational modelling ought to be employed.",
author = "Idowu, {Michael A.}",
year = "2012",
month = "2",
doi = "10.5504/BBEQ.2011.0142",
language = "English",
volume = "26",
pages = "2712--2715",
journal = "Biotechnology and Biotechnological Equipment",
issn = "1310-2818",
publisher = "Diagnosis Press Limited.",
number = "1",

}

TY - JOUR

T1 - Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. A role for systems biology approach in drug development. Part II - CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs

AU - Idowu, Michael A.

PY - 2012/2

Y1 - 2012/2

N2 - Cyclin-dependent kinases (CDKs) are key regulators of cell growth and proliferation. Impaired regulation of their activity leads to various diseases such as cancer and heart hypertrophy. Consequently, a number of CDKs are considered as targets for drug discovery. We review the development of inhibitors of CDK2 as anti-cancer drugs in the first part of the paper and in the second part, respectively, the development of inhibitors of CDK9 as potential therapeutics for heart hypertrophy. We argue that the above diseases are systems biology, or network diseases. In order to fully understand the complexity of the cell growth and proliferation disorders, in addition to experimental sciences, a systems biology approach, involving mathematical and computational modelling ought to be employed.

AB - Cyclin-dependent kinases (CDKs) are key regulators of cell growth and proliferation. Impaired regulation of their activity leads to various diseases such as cancer and heart hypertrophy. Consequently, a number of CDKs are considered as targets for drug discovery. We review the development of inhibitors of CDK2 as anti-cancer drugs in the first part of the paper and in the second part, respectively, the development of inhibitors of CDK9 as potential therapeutics for heart hypertrophy. We argue that the above diseases are systems biology, or network diseases. In order to fully understand the complexity of the cell growth and proliferation disorders, in addition to experimental sciences, a systems biology approach, involving mathematical and computational modelling ought to be employed.

U2 - 10.5504/BBEQ.2011.0142

DO - 10.5504/BBEQ.2011.0142

M3 - Article

VL - 26

SP - 2712

EP - 2715

JO - Biotechnology and Biotechnological Equipment

JF - Biotechnology and Biotechnological Equipment

SN - 1310-2818

IS - 1

ER -